Efficacy of transcatheter arterial embolization plus targeted chemotherapy for advanced hepatocellular carcinoma: A case report and literature review

Table 1 Dynamic changes in liver function during treatment

Date	ALT (IU/L)	AST (IU/L)	Clinical context
November 19, 2021 (Baseline)	106 ↑	68 ↑	Initial diagnosis, hepatic insufficiency
December 1, 2021	76 ↑	63 ↑	Pre-TAE, hepatoprotective therapy initiated
December 2, 2021	-	-	TAE procedure performed
December 5, 2021	148 ↑	73 ↑	Post-TAE peak ALT
December 11, 2021	46	79 ↑	Gradual recovery
December 29, 2021	130 ↑	144 ↑	Before cycle 2, transient elevation
January 3, 2022	89 ↑	157 ↑	Before cycle 2, AST peak
February 15, 2022	29	34	Normalized, chemotherapy resumed

ALT: Alanine aminotransferase; AST: Aspartate transaminase.

Table 2 Dynamic changes in hepatitis B virus DNA during treatment

Date	HBV-DNA (IU/mL)	Reference range
November 19, 2021 (Baseline)	2.58 × 106	< 1.0 × 10²
December 29, 2021	8.04 × 10²	< 1.0 × 10²
January 24, 2022	1.31 × 10²	< 1.0 × 10²
February 15, 2022	< 1.0 × 10² (normal)	< 1.0 × 10²

HBV-DNA: Hepatitis B virus DNA.

Table 3 Treatment-related adverse events graded according to CTCAE v5.0

Adverse event	CTCAE grade	Timing	Management	Outcome
Oxaliplatin hypersensitivity (generalized skin rash, nausea, retching)	Grade 2	Cycle 6	Anti-allergic and symptomatic treatment	Resolved
Elevated ALT (baseline 106 IU/L, peaked at 148 IU/L post-TAE, 130 IU/L during cycle 2)	Grade 1	Throughout treatment	Hepatoprotective therapy (glutathione, tiopronin, bicyclol, silymarin)	Normalized
Elevated AST (baseline 68 IU/L, peaked at 157 IU/L during cycle 2)	Grade 1	Throughout treatment	Hepatoprotective therapy	Normalized
Anlotinib-related adverse events (leukopenia, hypertension, hand-foot syndrome)	None	-	-	-

ALT: Alanine aminotransferase; AST: Aspartate transaminase; TAE: Transcatheter arterial embolization.